In US market on 23 September 2014
Dr Reddys Laboratories announced that the Company has launched Levalbuterol Inhalation Solution (for oral inhalation only), USP 0.31 mg/3 mL, 0.66 mg/ 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX inhalation solution in the US market on 23 September 2014, approved by the United States Food & Drug Administration (USFDA).Powered by Capital Market - Live News
